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Victories
More than 1,000 disease genes have been cloned and
their mutations characterized, including those that ac-
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count for the most common Mendelian disorders. While
this represents one glorious consequence of the global
genome initiatives, it also is a mere beginning.
Challenges
Clinical benefit from gene discoveries has so far been
limited. With the first great gene discoveries, such as the
cloning of the hemophilia A gene and the dystrophin
gene, large-scale germline molecular diagnostics was
born, and benefits to affected families were immediate
and substantial. However, did we imagine that in the
year 2002 there would still be no specific, gene-related
therapy, let alone cure? I did not.
Disappointments
The a priori expectation was that once the gene defect
was pinpointed, a drug or strategy would be designed
that overcomes the defect. Let us face the fact that this
has not yet occurred (with the notable exception of the
recent Gleevec story).
In the absence of breakthroughs that are directly
therapeutic, positive development has occurred as a re-
sult of improved diagnostics. For instance, early and
precise germline mutation detection in multiple endo-
crine neoplasia saves lives by way of preventative sur-
gery. However, these are relatively rare or very rare dis-
orders. The dream of larger scale prevention of some
adult-onset Mendelian diseases may soon become pos-
sible. In his presidential address to this Society in 1998,
A. Beaudet outlined in detail how such might be the
case with hemochromatosis (Beaudet 1998). Dr. Beau-
det also mentioned hereditary nonpolyposis colorectal
cancer (HNPCC) as a possible candidate for population-
based diagnosis and prevention. Below, I shall outline
my view of this possibility.
HNPCC—A Multiorgan Cancer Syndrome
Much of our present knowledge about HNPCC comes
from Dr. Henry Lynch, who pioneered the clinical study
of inherited forms of the common cancers. Character-
istics of HNPCC include dominant Mendelian inheri-
tance of predisposition, early-onset (usually believed to
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have a mean age of ∼44 years), synchronous tumors
(more than one primary tumor simultaneously), meta-
chronous tumors (more that one cancer during lifetime),
cancer in various organs (colorectum, endometrium,
stomach, ovary, uroepithelium, brain, biliary tract, lym-
phoma), and relatively good prognosis (Lynch and de la
Chapelle 1999).
Predisposition to HNPCC is caused by mutations in
one of several DNAmismatch-repair (MMR) genes. The
majority of clinically typical HNPCC is caused by mu-
tations in either MLH1 or MSH2, while mutations in
MSH6 and PMS2 are believed to be rare and give rise
to clinical features that are less typical (ICG-HNPCC
Web site). The MMR gene mutations obey the Knudson
principle, in that heterozygous carriers of a germline
mutation do not have disease. Somatic inactivation of
the wild-type allele (e.g., by deletion, mutation, or pro-
moter methylation) leads to MMR deficiency, which
triggers malignant transformation, presumably by allow-
ing spontaneously arising mutations in other genes to
accumulate. Why MMR deficiency–associated tumors
occur in some organs (e.g., colon, endometrium) and
not in others (e.g., lung, prostate) is debated. Likewise,
there is no definitive answer to the question why the
clinical outcome of colorectal cancer is more favorable
in HNPCC than in sporadic cases (Lynch and de la
Chapelle 1999).
Clinical surveillance of HNPCC mutation carriers is
beneficial. A 15-year study initiated in 1982 suggests
that surveillance by colonoscopy every 3 years signifi-
cantly reduces cancer morbidity (Ja¨rvinen et al. 2000).
The death rate was reduced by 66%. In the study of a
total of 252 individuals, there were, for instance, nine
deaths from colorectal cancer among those not sur-
veilled ( ) and no deaths from colorectal cancernp 119
in those surveilled ( 3). Thus, it follows logicallynp 13
that more lives can be saved the more carriers of
HNPCC can be diagnosed and clinically surveilled.
Detection of HNPCC
Previous diagnostic criteria were based on a combination
of family aggregation and early onset of colorectal can-
cer (Vasen et al. 1991). In well-developed health care
systems, individuals fulfilling these criteria will be noted
and offered genetic testing. When a proband with a mu-
tation is identified, at-risk family members will be of-
fered genetic testing, and further carriers (affected or
healthy) will be diagnosed.
The above scenario might be seen as traditional or
passive. It relies on a well-functioning, sophisticated
health care system and high awareness of genetics in
cancer. Even under ideal circumstances, it is capable of
detecting just a fraction of all HNPCC. The sensitivity
may be on the order of 30%.
Here, an untraditional or active approach to HNPCC
detection is proposed instead. It relies on microsatellite
instability (MSI) of the tumor as a molecular marker.
MSI arises as a result of MMR deficiency. MSI is found
in 12%–18% of all colorectal cancers and is readily
detectable by a simple test (Boland et al. 1998; de la
Chapelle 1999). MSI is highly sensitive for HNPCC
(80%–95%) (Aaltonen et al. 1994), but as many spo-
radic tumors also show MSI, the specificity is only
∼20%.
The proposed method is to test all colorectal cancers
for MSI and all individuals with an MSI-positive tumor
for MMR gene mutations. This scenario has been im-
plemented in Finland, where MSI was determined in the
tumors of 1,044 unselected consecutive colorectal can-
cer patients. The 129 MSI-positive cases (12%) were
studied for germline mutations in MLH1 and MSH2.
There were 28 mutation-positive individuals (i.e., new
cases of HNPCC) (Aaltonen et al. 1998; Salovaara et
al. 2000). Those 28 patients represented 22% of the
129 MSI-positive cases and 2.7% of all 1,044 patients
screened. Interestingly, only 9/28 (32%) patients had a
family history that fulfilled the traditional diagnostic
criteria for HNPCC (Vasen et al. 1991), confirming that
the sensitivity of these criteria to detect HNPCC is low.
The study revealed that at least 2.7% of all colorectal
cancer patients had HNPCC. Although this figure is an
underestimate for multiple reasons, it provides a first
estimate of the population frequency of MMR muta-
tions, 1:740. Finally, the study showed that the pro-
posed active approach was feasible.
Molecular Screening of All Colorectal Cancer Patients
as a Means of Diagnosing HNPCC
The above findings were obtained in Finland, a small
country with a relatively centralized health care system,
obligatory medical insurance, high general-education
level, and positive attitudes toward modern, including
genetic, medicine. It remains to be determined whether
a similar program can be implemented in circumstances
that are less favorable. In particular, does the American
health care system allow such studies? Are attitudes
among the population and health care professionals con-
ducive to similar programs? Finally, even if such studies
could be carried out, are they deemed as desirable as the
surveillance figures from Finland suggest?
There is probably no other way of answering this
question than by performing pilot studies in the United
States. One such study is under way in the region of
metropolitan Columbus, Ohio. Its ∼1.5 million popu-
lation is reasonably representative of the U.S. popula-
tion ethnically and socioeconomically. Most colorectal
cancer care is provided by six major hospitals, all lo-
cated in Columbus. The project is designed to accrue
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Figure 1 Molecular screening for HNPCC in the Columbus,
Ohio, metropolitan area.
as many newly diagnosed colorectal or endometrial car-
cinoma patients as possible in the six hospitals. The
design of the study is shown in figure 1. A total of 1,500
colorectal cancer patients and 450 endometrial cancer
patients will be entered into the study. Presently, 75%
of the accrual has occurred. Preliminary observations
can be reported as follows.
Accrual is ∼65% of all eligible patients. Differences
in accrual between the hospitals are large and decidedly
due to differences in the degree of dedication to the
study by the health professionals. The main reason for
noninclusion is not patient refusal but unintentional
noninclusion by personnel. Refusal to consent is most
often associated with old to very old age. The laboratory
procedures are highly standardized and the results read-
ily interpretable, with the exceptions discussed below.
Preliminary results, after near-complete analysis of∼30%
of the cases, suggest that the proportion of patients with
germlineMMRmutations will be equal to or higher than
in Finland (12.7%). This appears to be the case both in
colorectal and endometrial cancer.
Particular emphasis is given to the educational, coun-
seling, and family aspects of the study. Participating
professionals are regularly informed about the study.
Patients whose tumors are MSI negative, and patients
whose tumors are MSI positive but whose germline is
negative for MMR mutations, receive detailed written
feedback, including recommendations about clinical
surveillance.
Patients with confirmed or suspected disease-causing
mutations are seen by a genetic counselor and coun-
seled. The mutation is confirmed in a CLIA laboratory
from a new blood sample. A pedigree is drawn; family
members at 25% or higher a priori risk are offered
testing for the mutation found in the probands. So far,
some 100 relatives of 12 probands have been tested;
∼40% are mutation positive. Mutation-positive and
mutation-negative individuals are given recommenda-
tions regarding clinical surveillance and referred back
to their original physician.
Obstacles
Compliance, Feasibility, and Ethical Considerations
Subjective experience, so far, from the Columbus
study clearly suggests that patient attitudes are highly
positive. Fear of legal, professional, and insurance dis-
crimination is rare. A major factor determining inclusion
in the study is the degree of organizational involvement
and motivation of the hospital administrators, physi-
cians, and nurses. Another major factor is how the study
is presented to the patient; in other words, the profes-
sional skill and personality of the person dealing with
the patient during the consent procedure.
Accuracy and Interpretation of Mutation Detection
Mutations in MLH1, MSH2 and MSH6 are searched
for by genomic exon-by-exon sequencing. While this
does represent the present gold standard, notably, several
types of mutations are missed, including large deletions,
other structural abnormalities, and many changes caus-
ing splicing errors. Mutations missed in this way may
constitute as many as 20% of all disease-causing mu-
tations. Another major problem is the interpretation of
missense mutations, which account for some 30% of all
mutations in MLH1 and MSH6. Unfortunately, there
are no easy ways of dealing with the interpretation of
missense changes. One recent major technical advance
is the use of allele separation, also known as “conversion
to haploidy” (Yan et al. 2000). This often allows dele-
tions and splice-site mutations to be identified and in-
terpreted (Nakagawa et al. 2002). In some instances,
allele separation helps interpret missense mutations as
well.
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Table 1
Theoretical Outline of Molecular Screening for HNPCC in the United States:
Annual Outcome
Population
No. of patients newly diagnosed with colorectal cancer 140,000
No. of tumors tested for MSI 140,000
No. of patients with MSI of tumor (12%) 16,800
Search for mutations in MLH1, MSH2, MSH6 16,800
No. of patients with germline mutation (3%)p new HNPCC probands 4,200
No. of relatives at risk tested (10 per proband; test for proband’s mutation only) 42,000
No. of relatives with germline mutation (40%) 16,800
Total no. of new cases of HNPCC (4,200  16,800) 21,000
Ease and Accuracy of Clinical Surveillance
Experience from previous and ongoing studies sug-
gests that the sensitivity of colonoscopy to detect cancer
is high; however, the desirable interval between colon-
oscopies in mutation-positive individuals may be just
one year. Clearly, this creates a major logistic, economic,
and emotional burden. One alternative approach is pro-
phylactic subtotal colectomy, a relatively drastic pro-
cedure. A further method is the fecal occult blood test,
which is marred by low sensitivity and specificity.
Better methods must be sought. For instance, virtual
colonoscopy, if improved, could offer an alternative, per-
haps in conjunction with other tests, such as the deter-
mination of gene mutations in DNA extracted from the
stools. HNPCC mutation carriers may be particularly
important targets of such tests becauseMSI is detectable,
with high sensitivity and specificity (Traverso et al.
2002), and tumors are predominantly right sided.
Clinical surveillance of HNPCC gene carriers is chal-
lenging also because of the high risk of cancer in organs
other than the colorectum, in particular, the endome-
trium, stomach, and ovaries.
Nationwide Screening for HNPCC
Applying the above-referenced data from Finland to the
U.S. population, a nationwide screening program of all
newly diagnosed colorectal cancer patients could lead to
the detection of 21,880 new carriers of HNPCC mu-
tations each year (table 1). Is this realistic? Experience
gathered in the ongoing Columbus study suggests that
the scenario is conceptually, logistically, and clinically
possible to carry out. This does not mean that all cases
can be accrued. Economic issues are difficult to solve,
no matter how favorable the figures might look in a cost-
efficiency analysis. Finally, the health care system would
need to be reformed in order to accommodate and im-
prove the massive surveillance effort that would be
required.
Conclusion
Dealing with HNPCC is a real challenge to our society.
If the only choice in treatment and prevention were a
drug or vaccine that restores deficient mismatch repair
or gene therapy that “cures” the germline mutations,
hopes of success would be slim. The second-line ap-
proach described here, including improved diagnosis,
population-based molecular screening, and clinical sur-
veillance targeted at the highest risk groups, is realistic
and provides hope.
Acknowledgments
I thank Heather Hampel, CGC, for critical reading of the
manuscript. The author’s research is supported by grants
CA67941 and CA16058 from the National Cancer Institute.
Electronic-Database Information
Accession number and URL for data presented herein are as
follows:
http://www.nfdht.nl/ (for International Collaborative Group
on Hereditary Non-Polyposis Colorectal Cancer Web site)
References
Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A,
Peltoma¨ki P, Chadwick RB, Ka¨a¨ria¨nen H, Percesepe A, Ah-
tola H, Ha¨rko¨nen N, Julkunen R, Kangas E, Ojala S, Tu-
likoura J, Valkamo E, Eskelinen M, Ja¨rvinen H, Mecklin JP,
de la Chapelle A (1998) Incidence of hereditary nonpoly-
posis colorectal cancer and the feasibility of molecular
screening for the disease. New Engl J Med 338:1481–1487
Beaudet AL (1999) 1998 ASHG presidential address: making
genomic medicine a reality. Am J Hum Genet 64:1–13
Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Esh-
leman JR, Burt RW,Meltzer SJ, Rodriguez-BigasMA, Fodde
R, Ranzani GN, Srivastava S (1998) A National Cancer
Institute workshop on microsatellite instability for cancer
detection and familial predisposition: development of inter-
national criteria for the determination of microsatellite in-
stability in colorectal cancer. Cancer Res 58:5248–5257
240 Am. J. Hum. Genet. 72:236–240, 2003
de la Chapelle A (1999) Testing tumors for microsatellite in-
stability. Eur J Hum Genet 7:407–408
Ja¨rvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aal-
tonen LA, Peltoma¨ki P, de la Chapelle A, Mecklin J-P (2000)
Controlled 15-year trial on screening for colorectal cancer
in hereditary nonpolyposis colorectal cancer families. Gas-
troenterology 118:829–834
Lynch HT, de la Chapelle A (1999) Genetic susceptibility to
non-polyposis colorectal cancer. J Med Genet 36:801–818
Nakagawa H, Yan H, Lockman J, Hampel H, Kinzler KW,
Vogelstein B, de la Chapelle A (2002) Allele separation fa-
cilitates interpretation of potential splicing alterations and
genomic rearrangements. Cancer Res 62:4579–4582
Salovaara R, Loukola A, Kristo P, Ka¨a¨ria¨inen H, Ahtola H,
Eskelinen M, Ha¨rko¨nen N, Julkunen R, Kangas E, Ojala S,
Tulikoura J, Valkamo E, Ja¨rvinen H, Mecklin J-P, Aaltonen
LA, de la Chapelle A (2000) Population-based molecular
detection of hereditary nonpolyposis colorectal cancer. J Clin
Oncol 18:2193–2200
Traverso G, Shuber A, Olsson L, Levin B, Johnson C,Hamilton
SR, Boynton K, Kinzler KW, Vogelstein B (2002) Detection
of proximal colorectal cancers through analysis of faecal
DNA. Lancet 359:403–404
Vasen HF, Mecklin JP, Khan PM, Lynch HT (1991) The in-
ternational collaborative group on hereditary non-polyposis
colorectal cancer. Dis Colon Rectum 34:424–425
Yan H, Papadopoulos N,Marra G, Perrera C, Jiricny J, Boland
CR, Lynch HT, Chadwick RB, de la Chapelle A, Berg K,
Eshleman JR, Yuan W, Markowitz S, Laken SJ, Lengauer
C, Kinzler KW, Vogelstein B (2000) Conversion of diploidy
to haploidy. Nature 403:723–724
